Our Primary Focus: Patients

We Start Our Programs to Address Unmet Medical Needs that Improve the Quality of Life for Our Patients and their Families

Processa Pharmaceuticals is committed to improving the quality of life for patients with unmet medical needs. Our approach to development, always starts with the needs of the patient, from acquisition through development we are focused on intelligently designing and completing trials with critical data that permit efficient evaluation of the risk/benefit of our pharmacological solutions. We believe our de-risked approach leads to a higher probability of success; and when patients win, we all win.

Processa has acquired Vidya Therapeutics in a stock-for-stock transaction under a merger agreement, alongside an oversubscribed $200 million private placement financing.

Read more here
Learn more about our Product Pipeline

Processa Pharmaceuticals is a clinical-stage pharmaceutical company advancing differentiated therapeutic programs for immunological and inflammatory (I&I) diseases through a disciplined, science-driven development strategy. Following the acquisition of Vidya Therapeutics, Processa’s lead program is VT-7208, a potentially best-in-class oral Bruton’s tyrosine kinase inhibitor (BTKi) therapy designed to improve on efficacy and safety of earlier-generation BTKi programs. Processa is developing VT-7208 in food allergy, chronic spontaneous urticaria (CSU), relapsing multiple sclerosis (RMS) and exploring additional immune-mediated diseases. Processa’s second program is a potentially best-in-class, preclinical oral neonatal Fc receptor (FcRn) antagonist being explored for treatment of immune-mediated diseases.